Reading tissue status, the current literature reports a wide range of positivity rates for KRAS and GNAS mutations, with KRAS mutations detected in 31% to 88% of cases and GNAS mutations in 41% to 79% of resected IPMN patients [13, 24, 25, 26, 27, 28, 29]. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.